Clinical evidence
We offer a range of clinical Memokath studies, examples of which are listed below. Please contact us if you would like to access the full texts.
Pnn Medical acknowledge the importance of clinical evidence in today’s health care environment
Since their introduction to the market the Memokath™ stents have been widely covered in the literature.
Pnn Medical collaborates with leading health care institutions all over the world to provide clinical evidence to secure market entrance and for reimbursement and marketing purposes.
Pnn Medical is constantly seeking to improve the body of evidence and currently several clinical studies involving Memokath stents are ongoing in US, UK, Germany, France, Japan and Denmark.
Ease of removal of thermo-expandable prostate stents
Neil J. Barber, Alison J. Roodhouse, Per Rathenborg, Jørgen Nordling and Brian W. Ellis. BJU International, Vol. 96, September 2005.
Objective: To report the ease of removal of the Memokath® 028 prostatic stent (Engineers & Doctors A/S*, Denmark), an important attribute of the „ideal‟ prostatic stent.
Conclusions: These data show the ease of removal of the Memokath® 028 stent, reinforce its overall success in achieving the requirements of the ideal intraprostatic stent, and further emphasize the advantages of this implant over the epithelializing, permanent intraprostatic stent.
Thermo-expandable intraprostatic stents in blader outlet obstruction: An 8-year study
M.J.A. Perry, A.J. Roodhouse, A.B. Gidlow, T.G. Spicer and B.W. Ellis. BJU International, Vol. 90, May 2002.
Objective: To assess the use of a thermo- expandable intraprostatic stent (Memokath®, Engineers & Doctors A/S*, Denmark) for bladder outlet obstruction in men unable to undergo transurethral resection of the prostate (TURP), assessing symptoms, complications and duration of stent life.
Conclusion: The Memokath® intraprostatic stent is a valuable addition to the armamentarium of the urologist treating elderly or frail men with advanced bladder outlet obstruction and complements existing technologies.
Does the new spiral memokath® stent avoid repeated urethral strictures?
G. Riedasch, D. Motzkau, I. Drehmer, G. Staehler and K. Möhring. BJU International, Vol. 86, November 2000.
Objectives: The most troublesome longterm complications in using urethral stents are incrustation and growth of scarry tissue obstructing the lumen of the stent and urethra, respectively.
Conclusions: Contrary to “mesh stents”, the spiral Memokath® – stents seem to avoid transmural growth of the surrounding tissue. In fact, there is evidence, that by compressing the urethrotomised scar tissue a new, wide, totally epithelialised urethra is formed, thus avoiding secondary obstruction.
A novel long-term thermo expandable ureteric metal stent: Memokath™ 051 N. Buchholz et Al. British Journal of Urology. Int., 1-10. 2007
Objective: To examine the results of 42 cases treated by the authors. Strictures were benign in 29 cases and malignant in 9 cases, and bilateral in 4 patients. The article also presents a cost- comparison model between JJ and Memokath™ stent insertion.
Conclusions: The Memokath™ 051 stent seems to be an attractive cost effective treatment option both benign and malignant ureteric strictures. It has the advantages of immediate decompression and relief of obstructive uropathy symptoms while bearing minimal risk for bladder irritation, reflux and flank pain. There is no need for frequent stent replacement. Interestingly, a 20% rate of spontaneous stricture resolution could be related with the insertion of the Memokath™ 051 stent.